RxDoctor Payments Data

Thomas Rupp, MD

Gastroenterology · Grand Rapids, MINPI 1477593473

Payments from drug & device makers

$689in general payments, 2019–2025

Across 19 payments — averaging $36.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$236
  • AbbVie$175
  • Arthrex$140
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$58
  • Madrigal Pharmaceuticals$33
  • Takeda Pharmaceuticals U.S.A., Inc.$28
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$66296%
  • Education$284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$689 in reported general payments places this provider in the 35th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$62,364
Medicare patients
270
Services billed
617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab24$659,953
Humira PenAdalimumab14$155,482
OcalivaObeticholic Acid13$125,054
LinzessLinaclotide43$45,289
CreonLipase/Protease/Amylase14$43,258
Mesalamine ErMesalamine22$14,798
Mesalamine14$14,321
Mesalamine DrMesalamine15$12,377
Balsalazide Disodium34$11,206
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg388$9,712
Pantoprazole Sodium452$8,859
Ursodiol38$8,454
Azathioprine64$6,773
Sucralfate35$5,591
Omeprazole254$5,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$175$88,54757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →